The Pharmaceutical System
How the modern drug industry works. Pricing, research economics, GLP-1 societal effects, and the forces shaping what medicines exist and who can afford them.
(IQVIA, at prices before rebates; it projects more than $2.6T by 2030. The US accounts for close to half of global spend on a much smaller share of population)
(highly contested figure; independent estimates range from a few hundred million to several billion)
(KFF poll, March 2026; 12% were taking one at the time. "Ever used" and "currently using" get quoted interchangeably and are not the same number)
A note on framing. The pharmaceutical system is one of those domains where neither the "Big Pharma is uniquely evil" framing nor the "Big Pharma is the heroic developer of life-saving drugs" framing captures what is actually happening. The record has both heroic discoveries and pricing that critics call exploitative, both real R&D risk-taking and patent-extension maneuvers, both curative new therapies and a wellness-industry edge that has crossed over into outright misinformation. This page walks through how the system works so a reader can place specific stories - a price spike, a new approval, an enforcement action - in context.
How drug development works
Modern drug development moves through four roughly defined stages. Discovery, where chemists or biologists identify candidate molecules - traditionally through screening libraries of compounds, increasingly through computational and AI-assisted design. Preclinical development, where candidates are tested in cells and animals for both efficacy and toxicity. Clinical trials, which run in three phases (small safety trial, medium-sized efficacy trial, large-scale confirmatory trial) and consume the majority of the time and cost of the process. Regulatory approval, where the US Food and Drug Administration (FDA), the European Medicines Agency, or an equivalent national regulator reviews the trial data and decides whether to approve. The whole process averages about 10-15 years from candidate identification to approval, with a high attrition rate at every stage.
What this produces is an industry with an unusual cost structure. Most of the spending is on candidates that never reach approval. Most of the candidates that do reach approval take many years to recover their development costs. A small number of approved drugs - blockbusters earning more than $1 billion annually - generate the bulk of profits and effectively cross-subsidize the larger number of more modest products. This concentration shapes which diseases get studied, which patient populations get attention, and how aggressively prices are set on successful drugs.
The cost of developing a new drug is one of the most-debated numbers in health economics. The Tufts Center for the Study of Drug Development, which has industry funding, estimated in 2016 an average of about $2.6 billion per approved drug (in 2013 dollars, with substantial methodology choices). An independent 2020 study led by Olivier Wouters at the London School of Economics found a median of about $985 million and a mean of about $1.3 billion (in 2018 dollars). Critics including Aaron Kesselheim at Harvard and Marcia Angell argue that headline figures overstate what companies actually spend. Nearly half of the Tufts figure is the estimated cost of capital tied up over many years, and public funders such as the National Institutes of Health (NIH) pay for much of the basic science. On any estimate, development is expensive and risky, and public research contributes alongside the private spending the industry foregrounds.
The pricing puzzle
US prices for brand-name drugs are at least three times those in other rich countries even after rebates, and about 2.8 times across all drugs (RAND figures for 2022, published by the US health department). This is the most-discussed feature of the modern pharmaceutical system, and its explanation is relatively well understood. Most other developed countries negotiate drug prices through their single-payer or heavily-regulated health systems. The US long barred Medicare from negotiating most drug prices and has fragmented private negotiation across many payers with varying leverage.
The Inflation Reduction Act of 2022 began allowing Medicare to negotiate prices on a small subset of drugs. The first negotiated prices, for ten drugs, took effect on January 1, 2026; Medicare estimates they would have cut net spending on those drugs by 22% ($6 billion) had they applied in 2023. Fifteen more follow in 2027, including semaglutide (Ozempic, Wegovy) at $274 a month against a $959 list price, and 15 more in 2028. The industry lobbied to narrow the program and warned that it would cut research; its court challenges have failed, and the Supreme Court declined to hear them in May 2026. Whether negotiation lowers US prices durably, or is eroded by industry counter-action, is still being determined.
Pharmacy benefit managers (PBMs) - companies that act as middlemen between insurers and drug manufacturers - are a substantial and under-covered part of the US pricing system. The three largest (CVS Caremark, Express Scripts, OptumRx) handled 79% of US prescription claims in 2023. Their economic model involves opaque rebates and fee structures that move money in ways that are hard to audit; Federal Trade Commission (FTC) investigations since 2022 have repeatedly raised concerns about PBM business practices contributing to elevated prices. PBM reform, a rare area of bipartisan interest in US drug policy, has begun. Under a February 2026 law, PBMs in Medicare's drug plans will be paid flat fees from 2028 rather than amounts tied to drug prices. In 2026 Express Scripts and Caremark also settled the FTC's insulin-rebate case, agreeing to let patients' costs reflect rebates at the pharmacy counter.
Since 2025 the Trump administration has attacked the gap directly. By September 2026, 26 manufacturers covering 89% of the branded market, by the White House's count, had signed "most-favored-nation" deals. The deals benchmark Medicaid prices to those in other rich countries (and, the White House says, launch prices too) and list cash discounts on the government's TrumpRx.gov site, launched February 5, 2026; in return, signers are exempt from new drug tariffs until January 2029. The White House's economists expect $600 billion in savings over ten years, and consumer prices for prescription drugs were 2.9% lower in August 2026 than a year earlier (Bureau of Labor Statistics). Critics note that the terms are confidential and that most insured patients pay less through insurance than at TrumpRx prices. A Mass General Brigham analysis adds that signers believe the deals exempt them from two planned Medicare pricing models tied to prices abroad, which would erase nearly 80% of the models' projected savings. The industry shares the view that other rich countries free-ride on US prices; Britain agreed, in return for tariff relief, to raise the net price it pays for new medicines by 25%, and some companies have delayed European launches. Critics reply that the US premium reflects weak buyer power as much as a cross-subsidy of global R&D. Whether the premium is "fair" is a political question more than an economic one.
The patent system and what it rewards
Patents are the legal mechanism that lets pharmaceutical companies recover R&D investment by selling at prices well above marginal manufacturing cost. A new chemical entity typically receives 20 years of patent protection from the date of filing. The practical period of market exclusivity is much shorter - often around 8-12 years from approval - because filing happens early in development and the clock runs through the long clinical-trial period.
What the patent system actually rewards is more specific than "discovery." Companies receive patents on the molecule itself, on specific formulations (sustained-release, combination products), on methods of use, and increasingly on minor variations of approved drugs. The practice of "evergreening" - extending effective patent life through reformulations, combination products, or new indications shortly before the original patent expires - is well-documented. The most cited example is AbbVie's Humira, where a thicket of secondary patents extended US market exclusivity well beyond the original patent expiry. Biosimilar competition only began arriving in 2023, although Humira was approved in 2002.
Generic competition, when it arrives, typically reduces prices by 80-90% over a few years. The contrast between branded prices during patent exclusivity and generic prices after expiry is stark, and critics treat it as one of the more reliable arguments against the "drug development requires high prices" position. It shows how little of a branded price is manufacturing cost. The available evidence indicates that high prices during exclusivity reflect not just R&D recovery but also what the market will bear.
Biologics - drugs derived from living cells, including most cancer immunotherapies - are harder to copy than small molecules and have correspondingly longer effective exclusivity. Biosimilar competition typically reduces prices by 30-50% rather than 80-90%, so the end of exclusivity restrains costs less as biologics grow. A large cliff is nonetheless arriving: IQVIA expects patent expiries to cost branded drugs nearly $200 billion in sales through 2030. Companies facing such losses increasingly license drugs from China: deals signed by companies in greater China reached a record $137.7 billion in 2025, nearly ten times the 2021 level (Pharmcube data, via Reuters). The BIOSECURE Act of December 2025 restricts federal contracts involving listed Chinese biotechnology companies, but Treasury rules drafted in September 2026 would, Reuters reports, still permit most licensing deals.
GLP-1s and the Ozempic moment
The GLP-1 (glucagon-like peptide-1) receptor agonists - semaglutide (Ozempic, Wegovy, sold by Novo Nordisk) and tirzepatide (Mounjaro, Zepbound, sold by Eli Lilly) - are the most consequential pharmaceutical development of the mid-2020s. Originally approved for type 2 diabetes, they produced such dramatic weight loss that off-label and then approved obesity use expanded rapidly. Ongoing trials are showing additional benefits in cardiovascular disease, alcohol use disorder, kidney disease, and several other indications.
What makes GLP-1s significant goes beyond any single condition. They are the first widely-effective pharmaceutical for obesity, which affects roughly 40% of US adults and substantial fractions of populations in most developed economies. They appear to reduce craving behaviors more broadly, with implications for food-industry consumption patterns, alcohol consumption, and possibly addictive behaviors generally.
Supply and prices have changed quickly. The FDA declared the drugs' long shortages over by February 2025, ending the exemption that let pharmacies sell cheaper compounded copies, and has since moved against telehealth sellers of such copies. US list prices were about $1,000-1,350 a month; under a November 2025 White House deal, both makers cut cash prices through TrumpRx to about $350 a month, and the first obesity pills (Wegovy, December 2025; Lilly's Foundayo, April 2026) start at $149. Since July 2026 Medicare has covered some of the drugs for obesity at $50 a month to patients. Volumes have soared as prices fell: Lilly's second-quarter 2026 revenue rose 48% despite 13% lower prices, while Novo Nordisk expects its underlying 2026 sales to fall 4-12%. Where patents have expired, prices are lower still: generic semaglutide has sold in India from under $25 a month since March 2026.
The longer-term societal implications are still being mapped. If GLP-1 adoption keeps growing, the obesity rate in developed economies could decline meaningfully for the first time in decades; Gallup's self-reported US adult rate has already fallen from 39.9% in 2022 to 36.8% in 2026. Casey Means (nominated as US surgeon general in 2025) and Calley Means, with their wellness-industry-adjacent critique, have argued that GLP-1s are masking underlying lifestyle problems. This argument has both legitimate substance (the drugs are not a substitute for nutrition and movement) and an overstated dimension (lifestyle programs alone have not produced lasting weight loss for most people).
The opioid catastrophe and what it documented
The US opioid epidemic, which killed about 806,000 people from 1999 to 2023 according to the Centers for Disease Control and Prevention (CDC), was substantially driven by pharmaceutical-industry actions documented through extensive litigation and journalism. Purdue Pharma's marketing of OxyContin, beginning in 1996, included claims about low addiction risk that the company internally knew to be false. The Sackler family, which owned Purdue, took roughly $11 billion out of the company between 2008 and 2016, before its 2019 bankruptcy. After the Supreme Court rejected an earlier deal in 2024, a $7.4 billion settlement took effect on May 1, 2026. The Sacklers pay up to $7 billion of it over 15 years. The settlements fund treatment programs but leave the family much of its wealth, an outcome that critics including Patrick Radden Keefe (whose Empire of Pain documented the case) argued failed basic justice tests.
The case matters beyond opioids because it documented in court how the industry can operate when oversight is weak. Litigation exposed the role of pharmaceutical sales representatives in directing physician prescribing, of pharmacy benefit managers and distributors in maintaining supply, and of medical journals in publishing industry-favorable studies. It also exposed the role of patient-advocacy organizations, partly funded by industry, in shaping regulatory pressure. The reforms that followed (prescription drug monitoring programs, restrictions on direct-to-physician marketing, increased FDA scrutiny of opioid approvals) reduced new prescription rates but did not stop the deaths, which shifted from prescription opioids to heroin and then to fentanyl.
The fentanyl phase of the crisis is largely no longer a pharmaceutical-industry story; the supply is mostly Mexican-cartel-produced from Chinese precursors, covered on the Illicit Economies page. Overdose deaths have since fallen, to about 67,000 in the 12 months to April 2026, 40% below their 2023 peak (CDC provisional counts). But the epidemic's pharmaceutical-industry origins remain a recent example of what the system can do when regulation and accountability fail. The $50+ billion in eventual settlements is accountability of a kind; critics argue it is small beside the scale of harm caused.
The broader public-health interface
Pharmaceutical companies are not the only actors that determine what medicines exist and who can access them. The FDA and equivalent international regulators set approval standards, and the FDA has changed fast since 2025: staff cuts, "national priority vouchers" promising one-to-two-month reviews (Lilly's obesity pill was approved with one), and turnover at the top, including Commissioner Marty Makary's departure in May 2026. Supporters say the changes speed important drugs to patients; critics warn of political interference and rushed reviews. National health systems, insurers, and PBMs determine what is covered and at what price. Academic researchers and the NIH fund a substantial fraction of the basic science that pharmaceutical R&D builds on. Patient-advocacy organizations shape regulatory and political pressure. Journals and the broader medical-publishing system determine what evidence is widely seen.
The relationships between these actors have produced documented patterns of concern. Industry-funded physician education has shaped prescribing, as documents disclosed in litigation show. Industry-funded clinical trials tend to report more favorable results than independent trials of the same compounds. Patient-advocacy organizations range from fully independent to substantially industry-funded, with a mixed record on putting patients first. Reforms such as trial registration and open-data rules have had partial success.
The available evidence indicates substantial conflicts of interest in the pharmaceutical system. Some are partly necessary, since drug development is expensive and benefits from industry-academic collaboration; how to manage them is an ongoing policy challenge rather than a solved problem.
The paths from here
Continued slow reform with industry pushback
Medicare price negotiation expands to a larger drug list, 40 drugs by 2028. PBM reform proceeds incrementally. Patent-evergreening rules tighten modestly. The industry adapts business models without losing fundamental profitability. The US-international price gap narrows somewhat but persists. This is still the most likely trajectory, though the 2025-26 price deals, confidential agreements rather than law, may not outlast the current administration.
GLP-1s reshape the obesity-and-cardiometabolic landscape
Supply expansion catches up with demand. Insurance coverage broadens. Adoption reaches 25-40% of US adults. Obesity rates decline meaningfully for the first time in decades. Healthcare costs decline as cardiovascular events and diabetes complications fall. Food industry profits from highly-processed foods decline noticeably. This is the optimistic GLP-1 case. Parts are arriving (shortages over, prices falling, Medicare coverage since July 2026, self-reported US obesity down three points since 2022 in Gallup data); the rest depends on pricing and adherence over a long horizon.
A major safety event reshapes regulation
A previously unrecognized side effect of a widely-used drug class - GLP-1s, recent biologics, AI-assisted-discovery products - emerges at scale. The FDA approval process is reformed in response. Industry trial-design and pharmacovigilance practices change. Medical and political trust takes another hit. The Vioxx case (2004) is the recent precedent; the next case has not been identified but the conditions for one persist.
Geopolitical fragmentation hits the supply chain
US-China tension extends to pharmaceutical supply. China currently produces a substantial share of active pharmaceutical ingredients globally. Tariffs, export controls, or shipping disruption produces drug shortages. Reshoring efforts (already underway since COVID) accelerate but produce limited capacity in the medium term. Drug prices rise; specific shortages persist. Part of this has begun: citing national security, the US has phased in tariffs of up to 100% on imported patented drugs since July 31, 2026; generics, biosimilars and companies with pricing deals are exempt for now.
A wellness-skeptic-political alliance forces deeper change
The combination of populist health-skepticism and progressive critiques of the pharmaceutical industry produces unusual political coalitions. Reform that has been politically blocked - Medicare-for-all, broader price negotiation, restrictions on direct-to-consumer advertising (allowed only in the US and New Zealand) - becomes possible. The pharmaceutical-industry political position weakens substantially. Part of this has happened: Robert F. Kennedy Jr., who leads the Make America Healthy Again movement, runs the US health department; 26 drugmakers have signed price deals; and in September 2025 the FDA began a crackdown on what it calls deceptive drug advertising. Medicare-for-all and an advertising ban remain remote.
Where serious analysts disagree
The system produces genuine medical progress at high but defensible cost
The pace of pharmaceutical innovation - particularly in oncology, cardiometabolic disease, and rare diseases - has been substantial. The cost is real but reflects genuine R&D risk. Reforms should target specific abuses (PBM opacity, evergreening, direct-to-consumer advertising) without disrupting the basic incentive structure that produces the new drugs.
Held by: the mainstream of the industry's trade groups (the Pharmaceutical Research and Manufacturers of America, the Biotechnology Innovation Organization), much of the academic-medical research community, and several health economists including Joseph DiMasi (Tufts). The case has empirical support in the rate of new approvals; weaknesses in the magnitude of cost differentials.
The system is structurally extractive and needs major reform
The genuine medical progress comes substantially from publicly-funded basic research, with the private sector capturing disproportionate value through pricing power that does not reflect actual development cost. Major reform - Medicare-style negotiation across the board, public R&D pipelines for high-priority drugs, restrictions on patent evergreening - would produce comparable innovation at much lower cost.
Held by: Marcia Angell (former New England Journal of Medicine editor, "The Truth About the Drug Companies"), Dean Baker (Center for Economic and Policy Research), Mariana Mazzucato ("The Entrepreneurial State"), parts of the academic health-policy community. Has empirical support in the public-funding-of-basic-research data and weaknesses in fully accounting for genuine private-sector R&D risk.
The ultra-processed food industry is a larger health driver than pharmaceutical access
The chronic-disease epidemic that pharmaceutical drugs partly treat is largely a consequence of the modern food environment. Reforming pharmaceutical access without reforming the food system addresses symptoms rather than causes. GLP-1s are dramatic but expensive interventions that compensate for an environment that produces obesity. The right framing is food-and-pharmaceutical-system reform together, not separately.
Held by: Health Secretary Robert F. Kennedy Jr., whose 2025 commission report put ultra-processed diets first among four drivers of childhood chronic disease; Calley Means and Casey Means; parts of the public-health-prevention community; Robert Lustig (University of California, San Francisco); Mark Hyman. Has empirical support in the chronic-disease rate trajectory and weaknesses in cleanly attributing causation to specific food-environment changes.
PBMs are the most consequential underregulated actor
The opacity of pharmacy benefit manager pricing and rebate structures is responsible for a substantial fraction of US drug-pricing dysfunction. The "Big Three" PBMs (CVS Caremark, Express Scripts, OptumRx) extract value from both manufacturers and pharmacies in ways that are hard to audit. Meaningful reform of PBM operations would have larger effects on US prices than any other single intervention.
Held by: the FTC across two administrations, several state attorneys general including those in California and Texas, parts of the bipartisan congressional coalition pushing PBM reform legislation. The case has empirical support in FTC investigations and limitations in the technical complexity of PBM operations.
Conflict-of-interest concerns are systemically underweighted
Industry-funded education, industry-influenced clinical trials, industry-supported patient advocacy, and industry-funded medical journals collectively produce a research and prescribing environment that is more shaped by industry interests than the medical profession acknowledges. Reform requires structural separation of industry funding from physician education, prescribing decisions, and research evaluation.
Held by: Aaron Kesselheim (Harvard), the JAMA editorial position under recent leadership, Adriane Fugh-Berman, the broader BMJ and Cochrane evidence-quality community. Has empirical support in study-by-funder effect-size analyses; weaknesses in identifying alternative funding structures that would produce equivalent research.
What the available evidence actually supports: the pharmaceutical system produces genuine medical progress alongside pricing dysfunction. The cost-of-development numbers are real but inflate easily under industry framing. PBM practices are a documented source of US-specific cost and opacity, now starting to be regulated. Conflict-of-interest concerns are real and hard to fix. GLP-1s represent a possibly-transformative shift whose wider effects are still being mapped. And US pricing policy has moved more since 2022 than in the decades before, though much of the change rests on executive deals whose durability is uncertain.
What this means for you
If you take prescription medications
Generic substitution, when available, typically reduces cost by 80-90% without therapeutic difference. For drugs without generic alternatives, manufacturer patient-assistance programs are real and underused; pharmacy-pricing-comparison tools (GoodRx, Cost Plus Drugs) often produce substantially lower out-of-pocket prices than insurance-mediated pricing for many drugs, and for some brand-name drugs the cash price listed on TrumpRx.gov is worth comparing with your copay. Asking your pharmacist directly about lowest-cost options is reliably useful and is often not the default the pharmacy system offers.
If you are considering GLP-1 use
The decision is consequential and deserves substantive medical evaluation, not just internet research. The drugs work for most people who tolerate them; the side effects are real and meaningful; long-term durability of weight loss after discontinuation is poor without behavioral changes; prices have fallen and supply has stabilized, but coverage still varies. Your physician's individual experience with these drugs varies; a primary-care physician with substantial GLP-1 experience offers more continuity than most telehealth services.
If you encounter wellness-industry health advice
The boundary between legitimate critique of the pharmaceutical system and outright misinformation has been blurred by some major wellness-industry actors. The legitimate critique - that food environment matters, that lifestyle interventions are under-emphasized, that pharmaceutical solutions can mask underlying problems - is genuine. The misinformation - that vaccines cause autism, that nearly all medical advice is corrupt, that you can solve cancer with diet alone - is dangerous. Sources that engage critically with both pharmaceutical-industry capture and wellness-industry misinformation (Eric Topol's coverage is one example) are more reliable than either pure-defender or pure-critic positions.
If you read pharmaceutical-industry coverage
STAT News, Endpoints News, and the pharmaceutical coverage of Reuters and Bloomberg are widely used specialized sources. Investor-facing sources (Bloomberg, Financial Times) tend to cover the industry's economic and strategic moves more closely than consumer-facing sources, which often present industry framings with little scrutiny. Academic medical journals (the New England Journal of Medicine, JAMA, BMJ) are reliable on therapeutic evidence but less so on industry economics.
If you vote on pharmaceutical-related policy
The most consequential current policy areas are Medicare price negotiation expansion, the "most-favored-nation" deals and drug tariffs, PBM operational reform, patent-evergreening restrictions, and direct-to-consumer advertising rules. Pharmaceutical industry political contributions are large and bipartisan, so party affiliation predicts position on these questions less reliably than in other policy domains.
